Botulinum Toxin

Encyclopedia of Movement Disorders

Volumn , Issue , 2010, Pages 144-150

  Jankovic, J ^a  

^a Department of Neurology ^*  (United States)

Author keywords

Antibodies; Blepharospasm; Botulinum toxin; Bruxism; Cervical dystonia; Dystonia; Hemifacial spasm; Oromandibular dystonia; Sialorrhea; Spasmodic dysphonia; Tics; Tremor

Indexed keywords

EID: 85069827782     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374105-9.00098-8     Document Type: Chapter

References (14)

1. Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist 2008, 14:289-298.
2. Brin M.F., Comella C.L., Jankovic J., Lai F., Naumann M. CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Movement Disorders 2008, 23:1353-1360.
3. Hallett M. Potential new therapeutic indications for botulinum neurotoxins. Botulinum and Other Neurotoxins: Translating Science into Therapeutic Applications 2009, 367-373. Butterworth-Heinemann Elsevier, Philadelphia, PA. J. Jankovic, A. Albanese, M.Z. Atassi, J.O. Dolly, M. Hallett, N. Mayer (Eds.).
4. Jankovic J. Treatment of dystonia. Lancet Neurology 2006, 5:864-872.
5. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon 2008, 54(5):614-623.
6. Jankovic J. Treatment of hyperkinetic movement disorder. Lancet Neurology 2009, 8:844-856.
7. Kenney C., Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. Journal of Neural Transmission 2008, 115:585-591.
8. Lim E.C., Seet R.C. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurologica Scandinavica 2008, 117:73-84.
9. Molho E., Jankovic J., Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurologic Clinics 2008, (Supplement 1):43-53.
10. Roggenkamper P., Jost W.H., Bihari K., Comes G., Grafe S. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. Journal of Neural Transmission 2006, 113:303-312. for the NT 201 Blepharospasm Study Team.
11. Schulte-Mattler W.J. Use of botulinum toxin a in adult neurological disorders: Efficacy, tolerability and safety. CNS Drugs 2008, 22:725-738.
12. Sheffield J.K., Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Reviews Neurotherapeutics 2007, 7:637-647.
13. Simpson D.M., Blitzer A., Brashear A., et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699-1706.
14. Truong D.D., Jost W.H. Botulinum toxin: clinical use. Parkinsonism and Related Disorders 2006, 12:331-355.